A Class Act in Glaucoma Management: Differentiating Rho Kinase Inhibitors From the Pack

Access Activity

Overview / Abstract:

Medical management of glaucoma primarily focuses on lowering intraocular pressure (IOP) by decreasing aqueous production, reducing episcleral venous pressure, and/or increasing uveoscleral and trabecular outflow. Recently approved agents have expanded treatment options beyond the traditional mainstays of prostaglandin analogues and β-blockers, engaging Rho kinase (ROCK) inhibition to improve outcomes for patients with glaucoma. In this CE monograph, experts in the field will review the clinical and real-world data on ROCK inhibitor"based regimens for glaucoma, comparing monotherapy and combination therapy approaches for lowering IOP. Faculty will discuss the use of ROCK inhibitors to achieve individualized patient-specific treatment goals and review a clinical case to provide additional context for applying these therapies in practice.


May 25, 2024


Optometry / Ophthalmology CE



Credits / Hours



This continuing education activity is provided by Vindico Medical Education.

Presenters / Authors / Faculty

Jason Bacharach,

Inder Paul Singh,

Sarah Van Tassel

Sponsors / Supporters / Grant Providers

This activity is supported by an educational grant from Aerie Pharmaceuticals, Inc.

Keywords / Search Terms

Vindico Medical Education glaucoma, management, differentiating Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map